Guo Juan, Su Jiying, He Qi, Li Xiao, Zhao Youshan, Gu Shucheng, Fei Chengming, Chang Chunkang
a Department of Hematology , Shanghai Jiao Tong University Affiliated Sixth People's Hospital , China.
Hematology. 2016 Apr;21(3):152-61. doi: 10.1179/1607845415Y.0000000010. Epub 2016 Feb 24.
The aim of this study was to evaluate the prognostic impact of immunophenotyping in patients with multiple myeloma (MM), as well as other markers of disease, such as serum hyaluronan and cytogenetic aberrancies.
We have prospectively analyzed the prognostic impact of antigenic markers, assessed by multiparametric flow cytometry (MFC), in a series of newly diagnosed MM patients (n = 79).
Our results show that the expression of CD44, CD45, and CD28 and the absence of CD117 were associated with a significantly shorter progression free-survival (PFS). Clinical characteristics were collected; Cytogenetic aberrancies were assessed in 40 patients. Multivariate survival analyses identified that the CD117(-), CD28(+), CD45(+), and the percentage of bone marrow plasma cells by MFC are survival predictor, along with the International Staging System stage. Interestingly, the CD117(-) patients were associated with chromosomal aberrancies, including del (17p), +1q21, and IgH translocations.
The incorporation of multiparameter flow cytometry immunophenotyping into the routine diagnostic evaluation of MM patients can help to identify patients at a high risk of progression.
本研究旨在评估免疫表型分析对多发性骨髓瘤（MM）患者的预后影响，以及其他疾病标志物，如血清透明质酸和细胞遗传学异常的影响。
我们前瞻性地分析了通过多参数流式细胞术（MFC）评估的抗原标志物对一系列新诊断的MM患者（n = 79）的预后影响。
我们的结果表明，CD44、CD45和CD28的表达以及CD117的缺失与无进展生存期（PFS）显著缩短相关。收集了临床特征；对40例患者进行了细胞遗传学异常评估。多变量生存分析确定，CD117（-）、CD28（+）、CD45（+）以及MFC检测的骨髓浆细胞百分比是生存预测指标，与国际分期系统分期一样。有趣的是，CD117（-）患者与染色体异常相关，包括del（17p）、+1q21和IgH易位。
将多参数流式细胞术免疫表型分析纳入MM患者的常规诊断评估中，有助于识别进展风险高的患者。
